Tango Therapeutics
MA - CambridgeBiotechnology
Focus: Tango Therapeutics is a Cambridge-based oncology-focused biotech developing cancer immunotherapies and targeted approaches. The company operates as a clinical-stage player with a diversified pipeline across solid tumors.
Profile data last refreshed 17h ago · AI intelligence enriched 3d ago
Open Jobs
4-6 this month
Cooling — net -6 jobs in 30d
3 added, 9 removed. Slower than typical.
Should You Work at Tango Therapeutics?
AI assessmentTango is a bet on clinical-stage oncology with public-market credibility but significant execution risk; best suited for scientists seeking early-stage impact and equity upside over near-term revenue stability.
Why Work Here
- Public company (NASDAQ: TNGX) with recent strong stock performance (best-performing healthcare stock in March 2026), providing liquidity and market validation.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
7 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
S095035
MTAP-deleted Solid TumorsPHASE_1_2
Clinical Trials (1)
Help build intelligence for Tango Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.